BG60262B1 - Метод за получаване на заместени двупръстенни съединения - Google Patents

Метод за получаване на заместени двупръстенни съединения

Info

Publication number
BG60262B1
BG60262B1 BG070749A BG7074985A BG60262B1 BG 60262 B1 BG60262 B1 BG 60262B1 BG 070749 A BG070749 A BG 070749A BG 7074985 A BG7074985 A BG 7074985A BG 60262 B1 BG60262 B1 BG 60262B1
Authority
BG
Bulgaria
Prior art keywords
salt
compounds
preparation
stereoisomers
formula
Prior art date
Application number
BG070749A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG60262B2 (en
Inventor
Leslie Browne
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BG60262B2 publication Critical patent/BG60262B2/xx
Publication of BG60262B1 publication Critical patent/BG60262B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG070749A 1984-06-20 1985-06-19 Метод за получаване на заместени двупръстенни съединения BG60262B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/622,421 US4617307A (en) 1984-06-20 1984-06-20 Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors

Publications (2)

Publication Number Publication Date
BG60262B2 BG60262B2 (en) 1994-03-31
BG60262B1 true BG60262B1 (bg) 1994-03-31

Family

ID=24494112

Family Applications (7)

Application Number Title Priority Date Filing Date
BG070749A BG60262B1 (bg) 1984-06-20 1985-06-19 Метод за получаване на заместени двупръстенни съединения
BG097012A BG60352B2 (bg) 1984-06-20 1992-10-22 Метод за получаване на тетрахидропроизводни на заместени двупръстенни съединения
BG097011A BG60307B2 (en) 1984-06-20 1992-10-22 Method for obtaining of substituted two-ring compounds
BG097009A BG60305B2 (bg) 1984-06-20 1992-10-22 Метод за получаване на заместени двупръстенни съединения
BG097013A BG60353B2 (bg) 1984-06-20 1992-10-22 Метод за получаване на заместени двупръстенни съединения
BG097010A BG60306B2 (bg) 1984-06-20 1992-10-22 Метод за получаване на заместени двупръстенни съединения
BG098213A BG60402B2 (bg) 1984-06-20 1993-11-11 Заместени бициклични съединения

Family Applications After (6)

Application Number Title Priority Date Filing Date
BG097012A BG60352B2 (bg) 1984-06-20 1992-10-22 Метод за получаване на тетрахидропроизводни на заместени двупръстенни съединения
BG097011A BG60307B2 (en) 1984-06-20 1992-10-22 Method for obtaining of substituted two-ring compounds
BG097009A BG60305B2 (bg) 1984-06-20 1992-10-22 Метод за получаване на заместени двупръстенни съединения
BG097013A BG60353B2 (bg) 1984-06-20 1992-10-22 Метод за получаване на заместени двупръстенни съединения
BG097010A BG60306B2 (bg) 1984-06-20 1992-10-22 Метод за получаване на заместени двупръстенни съединения
BG098213A BG60402B2 (bg) 1984-06-20 1993-11-11 Заместени бициклични съединения

Country Status (31)

Country Link
US (1) US4617307A (enExample)
EP (1) EP0165904B1 (enExample)
JP (1) JPS6112688A (enExample)
KR (1) KR900008566B1 (enExample)
AT (1) ATE62415T1 (enExample)
AU (1) AU589565B2 (enExample)
BG (7) BG60262B1 (enExample)
CA (1) CA1276633C (enExample)
CS (1) CS268672B2 (enExample)
CY (1) CY1750A (enExample)
DD (1) DD237510A5 (enExample)
DE (1) DE3582452D1 (enExample)
DK (1) DK170302B1 (enExample)
DZ (1) DZ799A1 (enExample)
ES (6) ES8702406A1 (enExample)
FI (1) FI80694C (enExample)
GR (1) GR851487B (enExample)
HK (1) HK23494A (enExample)
HU (1) HU202529B (enExample)
IE (1) IE58070B1 (enExample)
IL (1) IL75546A (enExample)
MA (1) MA20459A1 (enExample)
MX (1) MX9203369A (enExample)
NO (1) NO162467C (enExample)
NZ (1) NZ212483A (enExample)
PH (1) PH23390A (enExample)
PL (6) PL145103B1 (enExample)
PT (1) PT80661B (enExample)
RO (1) RO92583A (enExample)
SU (6) SU1433413A3 (enExample)
ZA (1) ZA854615B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428160A (en) * 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
GB8510541D0 (en) * 1985-04-25 1985-05-30 Wyeth John & Brother Ltd Heterocyclic compounds
US5171858A (en) * 1985-06-05 1992-12-15 Schering A.G. Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines
US4937250A (en) * 1988-03-07 1990-06-26 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4797411A (en) * 1986-07-18 1989-01-10 Farmitalia Carlo Erba S.P.A. Cycloalkyl-substituted 4-pyridyl derivatives and use as aromatase inhibitors
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
US5066656A (en) * 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
EP0514015A1 (en) * 1991-04-19 1992-11-19 Merck & Co. Inc. Control of sex differentiation in fish
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
JPH05176659A (ja) * 1991-04-26 1993-07-20 Merck & Co Inc 家禽における雌性表現型を転換するために抗ミュラー管ホルモンを単独またはアロマターゼ阻害剤と組合せて使用する方法
WO1995028156A1 (en) * 1994-04-14 1995-10-26 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
EP0684235A1 (en) * 1994-05-27 1995-11-29 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
DE4432106A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20060069067A1 (en) * 2002-07-30 2006-03-30 Bhatnagar Ajay S Combination of an aromatase inhibitor with a bisphosphonate
ATE335744T1 (de) * 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
AU2003292039A1 (en) * 2002-11-18 2004-06-15 Novartis Ag Imidazo(1, 5a)pyridine derivatives and methods for treating aldosterone mediated diseases
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1977741A3 (en) 2004-03-17 2009-10-14 Novartis AG Use of renin inhibitors in therapy
EP1749006A2 (en) * 2004-05-28 2007-02-07 Speedel Experimenta AG Heterocyclic compounds and their use as aldosterone synthase inhibitors
BRPI0511621A (pt) * 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
WO2007139992A2 (en) * 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
EP2049517B1 (en) 2006-07-20 2013-11-27 Novartis AG Amino-piperidine derivatives as cetp inhibitors
CN101506216A (zh) * 2006-08-25 2009-08-12 诺瓦提斯公司 用于治疗由醛固酮合酶和/或11-β-羟化酶和/或芳香酶介导的病症的稠合的咪唑衍生物
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
HRP20120476T1 (hr) 2007-11-05 2012-06-30 Novartis Ag Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza
EA017939B1 (ru) 2007-12-03 2013-04-30 Новартис Аг Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AR086665A1 (es) * 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
ES2683350T3 (es) 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
PE20142358A1 (es) 2012-01-17 2015-01-30 Novartis Ag Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
DK3250555T3 (da) * 2015-01-29 2021-04-26 Recordati Ag Fremgangsmåde til fremstillingen af kondenserede imidazoloderivater
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
JP2016074729A (ja) * 2015-12-31 2016-05-12 国立大学法人 千葉大学 イミダゾリウム塩及びそれを用いた不斉合成触媒並びにイミダゾリウム塩の製造方法
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
IL301471B2 (en) * 2016-10-27 2025-02-01 Damian Pharma Ag Aldosterone synthase inhibitor
WO2018078049A1 (en) 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
SG11202010906XA (en) 2018-05-03 2020-12-30 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
CN113166204B (zh) 2018-11-27 2025-01-28 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5124517B1 (enExample) * 1971-03-15 1976-07-24
FR2449689A1 (fr) * 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
FI75569C (fi) * 1981-06-22 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av terapeutiskt verkande imidazo/1,5-a/pyridiner.
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
US4409226A (en) * 1981-10-05 1983-10-11 Schering Corporation Imidazo[1,5-a]pyridines
US4361567A (en) * 1981-10-05 1982-11-30 Schering Corporation Treatment of peptic ulcer disease
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors

Also Published As

Publication number Publication date
KR900008566B1 (ko) 1990-11-24
BG60305B2 (bg) 1994-07-25
ES555539A0 (es) 1988-04-01
ES555541A0 (es) 1987-11-16
ES8702406A1 (es) 1987-01-01
FI80694B (fi) 1990-03-30
SU1433413A3 (ru) 1988-10-23
JPS6112688A (ja) 1986-01-21
PT80661A (en) 1985-07-01
PL145103B1 (en) 1988-08-31
FI80694C (fi) 1990-07-10
DK277685D0 (da) 1985-06-19
BG60262B2 (en) 1994-03-31
CS268672B2 (en) 1990-04-11
IL75546A0 (en) 1985-10-31
EP0165904A2 (de) 1985-12-27
ES555540A0 (es) 1987-12-16
ZA854615B (en) 1986-02-26
SU1482530A3 (ru) 1989-05-23
MA20459A1 (fr) 1985-12-31
ES8802049A1 (es) 1988-03-16
NZ212483A (en) 1988-10-28
KR860000299A (ko) 1986-01-27
CS444985A2 (en) 1989-07-12
PL145814B1 (en) 1988-11-30
ES8802155A1 (es) 1988-04-01
DE3582452D1 (de) 1991-05-16
IL75546A (en) 1990-01-18
FI852399A0 (fi) 1985-06-17
AU4385785A (en) 1986-01-02
CA1276633C (en) 1990-11-20
DD237510A5 (de) 1986-07-16
PL145087B1 (en) 1988-08-31
DZ799A1 (fr) 2004-09-13
ES544344A0 (es) 1987-01-01
ATE62415T1 (de) 1991-04-15
US4617307A (en) 1986-10-14
PL145348B1 (en) 1988-09-30
FI852399L (fi) 1985-12-21
IE58070B1 (en) 1993-06-30
ES8802048A1 (es) 1988-03-16
BG60352B2 (bg) 1994-11-30
NO162467B (no) 1989-09-25
JPH047746B2 (enExample) 1992-02-12
SU1436879A3 (ru) 1988-11-07
NO852474L (no) 1985-12-23
PL254099A1 (en) 1986-09-09
HU202529B (en) 1991-03-28
BG60353B2 (bg) 1994-11-30
EP0165904B1 (de) 1991-04-10
MX9203369A (es) 1992-09-01
IE851520L (en) 1985-12-20
NO162467C (no) 1990-01-10
ES8800681A1 (es) 1987-11-16
PL145104B1 (en) 1988-08-31
PT80661B (en) 1987-05-04
BG60306B2 (bg) 1994-07-25
PH23390A (en) 1989-07-26
HUT37936A (en) 1986-03-28
RO92583A (ro) 1987-11-30
EP0165904A3 (en) 1987-09-09
CY1750A (en) 1994-06-03
ES555538A0 (es) 1988-03-16
SU1443802A3 (ru) 1988-12-07
HK23494A (en) 1994-03-25
AU589565B2 (en) 1989-10-19
GR851487B (enExample) 1985-11-25
DK277685A (da) 1985-12-21
ES8801262A1 (es) 1987-12-16
DK170302B1 (da) 1995-07-31
BG60307B2 (en) 1994-07-25
SU1436880A3 (ru) 1988-11-07
PL145105B1 (en) 1988-08-31
BG60402B2 (bg) 1995-02-28
ES555542A0 (es) 1988-03-16
SU1436878A3 (ru) 1988-11-07

Similar Documents

Publication Publication Date Title
BG60262B1 (bg) Метод за получаване на заместени двупръстенни съединения
YU155290A (sh) Dusikove spojine
BG50272A3 (en) Method for the preparation of (d)- alpha- ethyl- 2- oxo- 1- pyrolydinacetamide
JPS5724335A (en) Novel p-substituted-3-phenoxy-1- alkylaminopropanol-2 compound
FR2592879B1 (fr) Nouveaux derives de la decahydroquinoleine, leur procede de preparation, les intermediaires de preparation, leur application a titre de medicaments et les compositions les renfermant
ES2001703A6 (es) Procedimiento para la preparracion de derrrivados de acidos 2-(2-imidazolin -2-il)- piridin -3- carboxilicos.
PT87277A (pt) Process for the preparation of new bicyclic compounds and pharmaceutical compositions comprising same
FR2394522A1 (fr) Nouveaux derives d'acides (s-phenenyl tris(carbonylimino))-5,5',5''tri-benzene-carboxyliques utiles notamment comme inhibiteurs du complement, et leur procede de preparation
KR910009714A (ko) 면역자극성 6-아릴-5,6-디하이드로이미다조[2,1-b]티아졸 유도체
JPS5724334A (en) Novel substituted 3-phenoxy-1-alkoxycarbonyl alkylamino-propanol-2 compound
EA200100816A1 (ru) 2-аминопиридины, содержащие конденсированные кольца в качестве заместителей
DE3683822D1 (de) Chartreusinderivate und salze, diese enthaltende antitumorzusammensetzungen und verfahren zu ihrer herstellung.
RU95101437A (ru) Содержащее производные 3-фенилсульфонил-3,7-диазабицикло [3,3,1] нонана лекарственное средство, способ получения производных 3-фенилсульфонил-3,7-диазабицикло-[3,3,1]-нонана
EP0050671A4 (en) THIAZOLE (3,2-a) PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM.
RU94046310A (ru) Эфиры никотиновой кислоты, способ их получения, способ получения промежуточных соединений, фармацевтическая композиция и способ лечения
HUT37756A (en) Process for preparing 1,4-dihydro-pyridina derivatives
BG50160A3 (en) Method for preparing of alcandiol dicarboxilates
ES8106517A1 (es) Procedimiento para la preparacion de nuevos derivados de 10-halogen-e-homo-eburnanos.
ES8702399A1 (es) Un procedimiento para preparar derivdos de 1,5-benzoxatiepina
ES8801296A1 (es) Un procedimiento para preparar derivados organicos de fosforo y oro.
ES8900230A1 (es) Procedimiento para la obtencion de derivados de piridazo-(1,2-a)(1,2)diacepina
ES8401062A1 (es) Procedimiento para la preparacion de nuevas 1-furil-3,4-dihidroisoquinoleinas.
IT1205114B (it) 2-selenometil-1,4-diidropiridine,procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
ES8103092A1 (es) Un procedimiento para la preparacion de derivados del acido aminodesoxi-clavulanico
SU1282506A1 (ru) 2-(3',4',5'-триметоксифенил)-1-метилимидазо (4,5-с)пиридингидрохлорид, обладающий спазмолитической и гипотензивной активностью